ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Japan's Takara Bio to build another COVID vaccine factory

Company aims for 73m doses by fiscal 2027 to become dominant producer

Japanese biotech company Takara Bio plans to build a new factory to add to its existing plant with the aim of producing 73 million doses of COVID vaccine by fiscal 2027. 

OSAKA -- Japanese biotech company Takara Bio will ramp up investment in its contract drug manufacturing business and build a new COVID vaccine plant to expand production capacity at its headquarters in Kusatsu, Shiga prefecture.

Under the plan, the biotech company hopes to produce 73 million doses of COVID vaccines in fiscal 2027, making it one of the largest contract vaccine manufacturers in Japan.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more